GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (ASX:TLX) » Definitions » Cash Flow from Financing

Telix Pharmaceuticals (ASX:TLX) Cash Flow from Financing : A$7.6 Mil (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Telix Pharmaceuticals Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jun. 2024, Telix Pharmaceuticals received A$0.6 Mil more from issuing new shares than it paid to buy back shares. It received A$2.3 Mil from issuing more debt. It paid A$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received A$0.0 Mil from paying cash dividends to shareholders. It spent A$0.7 Mil on other financial activities. In all, Telix Pharmaceuticals earned A$2.2 Mil on financial activities for the six months ended in Jun. 2024.


Telix Pharmaceuticals Cash Flow from Financing Historical Data

The historical data trend for Telix Pharmaceuticals's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Cash Flow from Financing Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only 42.72 34.12 2.85 174.96 10.19

Telix Pharmaceuticals Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 171.17 3.79 4.70 5.49 2.15

Telix Pharmaceuticals Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Telix Pharmaceuticals's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Telix Pharmaceuticals's Cash from Financing for the quarter that ended in Jun. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$7.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telix Pharmaceuticals  (ASX:TLX) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Telix Pharmaceuticals's issuance of stock for the six months ended in Jun. 2024 was A$0.6 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Telix Pharmaceuticals's repurchase of stock for the six months ended in Jun. 2024 was A$0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Telix Pharmaceuticals's net issuance of debt for the six months ended in Jun. 2024 was A$2.3 Mil. Telix Pharmaceuticals received A$2.3 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Telix Pharmaceuticals's net issuance of preferred for the six months ended in Jun. 2024 was A$0.0 Mil. Telix Pharmaceuticals paid A$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Telix Pharmaceuticals's cash flow for dividends for the six months ended in Jun. 2024 was A$0.0 Mil. Telix Pharmaceuticals received A$0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Telix Pharmaceuticals's other financing for the six months ended in Jun. 2024 was A$-0.7 Mil. Telix Pharmaceuticals spent A$0.7 Mil on other financial activities.


Telix Pharmaceuticals Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Telix Pharmaceuticals Business Description

Traded in Other Exchanges
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.